Fig. 7

Enhanced effect on cell proliferation inhibition, apoptosis induction and cell cycle arrest after co-treatment with nutlin-3a and apcin in Z138 and JVM2 cells. A After healthy PBMCs, Z138 and JVM2 cells co-treated with 1 μM nutlin-3a and 50 μM apcin for 48 h, cell viability was assessed by CCK-8 assay. B After Z138 and JVM2 cells co-treated with 1 μM nutlin-3a and 50 μM apcin for 48 h, the EdU incorporation rate was tested by flow cytometry to determine the cell proliferation condition. C Z138 and JVM2 cells were treated with 1 μM nutlin-3a and 50 μM apcin in combination for 48 h, and the apoptosis rate was quantified by flow cytometry based on Annexin V-FITC/PI staining. D After co-treatment with 1 μM nutlin-3a and 50 μM for 48 h, the changes of MMP in Z138 and JVM2 cells were detected by flow cytometry based on the JC-1 fluorescent probe. E Targeted protein expression by WB analysis after 48 h co-treatment with 2.5 μM nutlin-3a and 50 μM apcin in Z138 and JVM2 cells. The above data were obtained from at least three independent experiments and presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. F After Z138 and JVM2 cells co-treated with 2.5 μM nutlin-3a and 50 μM apcin for 48 h (Z138) or 72 h (JVM2), the proportion of G0/G1, S and G2/M phases in the cell cycle was analyzed by PI flow cytometry. Data were obtained from at least three independent experiments and presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the control group